



US009410917B2

(12) **United States Patent**
Beer et al.

(10) **Patent No.:** **US 9,410,917 B2**
(45) **Date of Patent:** **Aug. 9, 2016**

(54) **METHOD OF USING A BIOSENSOR**

USPC 204/403.01–403.15; 205/777.5
See application file for complete search history.

(71) Applicant: **Bayer HealthCare LLC**, Whippany, NJ
(US)

(56) **References Cited**

(72) Inventors: **Greg P. Beer**, Cassopolis, MI (US);
Huan-Ping Wu, Granger, IN (US);
Kin-Fai Yip, Elkhart, IN (US)

U.S. PATENT DOCUMENTS

(73) Assignee: **Ascensia Diabetes Care Holdings AG**,
Basel (CH)

3,420,205	A	1/1969	Morrison
3,505,136	A	4/1970	Attwood
3,510,268	A	5/1970	Hach
3,551,295	A	12/1970	Dyer
3,573,139	A	3/1971	Eiji Mori et al.
3,621,381	A	11/1971	Eckfeldt

(Continued)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 332 days.

FOREIGN PATENT DOCUMENTS

(21) Appl. No.: **14/193,214**

CA	2423837	10/2000
CA	2358993	5/2001

(22) Filed: **Feb. 28, 2014**

(Continued)

(65) **Prior Publication Data**

US 2014/0174951 A1 Jun. 26, 2014

Related U.S. Application Data

(62) Division of application No. 10/590,765, filed as
application No. PCT/US2005/003622 on Feb. 4, 2005,
now Pat. No. 8,696,880.

(60) Provisional application No. 60/542,362, filed on Feb.
6, 2004.

(51) **Int. Cl.**

G01N 33/487 (2006.01)
G01N 27/327 (2006.01)
C12Q 1/00 (2006.01)

(52) **U.S. Cl.**

CPC **G01N 27/3271** (2013.01); **C12Q 1/004**
(2013.01); **C12Q 1/006** (2013.01); **G01N**
27/3272 (2013.01); **G01N 27/3274** (2013.01)

(58) **Field of Classification Search**

CPC G01N 27/3271; G01N 27/3272; G01N
27/3274; C12Q 1/006; C12Q 1/004

OTHER PUBLICATIONS

Dalrymple-Alford, P., et al., "Peak Shapes in Semi-differential
Electroanalysis", "Anal. Chem.", 1977, pp. 1390-1394, vol. 49, No.
9, Publisher: American Chemical Society, Published in: USA.

(Continued)

Primary Examiner — Keith Hendricks


Assistant Examiner — Kourtney S Carlson

(74) *Attorney, Agent, or Firm* — Nixon Peabody LLP

(57) **ABSTRACT**

A biosensor (102) for determining the presence or amount of
a substance in a sample and methods of use of the biosensor
(102) are provided. The biosensor (102) for receiving a user
sample to be analyzed includes a mixture for electrochemical
reaction with an analyte. The mixture includes an enzyme, a
mediator and an oxidizable species as an internal reference.

26 Claims, 10 Drawing Sheets



(56)

References Cited

U.S. PATENT DOCUMENTS

3,715,192	A	2/1973	Wenz et al.	4,628,193	A	12/1986	Blum
3,720,093	A	3/1973	Gill	4,642,295	A	2/1987	Baker
3,763,422	A	10/1973	MacPhee et al.	4,648,665	A	3/1987	Davis et al.
3,770,607	A	11/1973	Williams	4,652,830	A	3/1987	Brown
3,776,832	A	12/1973	Oswin et al.	4,654,197	A	3/1987	Lilja et al.
3,791,933	A	2/1974	Moyer et al.	4,671,288	A	6/1987	Gough
3,791,988	A	2/1974	Bauer et al.	4,676,653	A	6/1987	Strohmeier et al.
3,838,033	A	9/1974	Mindt et al.	4,679,562	A	7/1987	Luksha
3,902,970	A	9/1975	Levin	4,680,268	A	7/1987	Clark, Jr.
3,917,453	A	11/1975	Milligan et al.	4,682,602	A	7/1987	Prohaska
3,919,627	A	11/1975	Allen	4,686,479	A	8/1987	Young et al.
3,920,580	A	11/1975	Mast	4,703,017	A	10/1987	Campbell et al.
3,925,183	A	12/1975	Oswin et al.	4,703,756	A	11/1987	Gough et al.
3,937,615	A	2/1976	Clack et al.	4,713,347	A	12/1987	Mitchell et al.
3,948,745	A	4/1976	Guillbault et al.	4,714,874	A	12/1987	Morris et al.
3,980,437	A	9/1976	Kishimoto et al.	4,721,677	A	1/1988	Clark, Jr.
4,005,002	A	1/1977	Racine et al.	4,729,959	A	3/1988	Ryan
4,008,448	A	2/1977	Muggli	4,731,726	A	3/1988	Allen et al.
4,040,908	A	8/1977	Clark, Jr.	4,734,184	A	3/1988	Burleigh et al.
4,053,381	A	10/1977	Hamblen et al.	4,745,076	A	5/1988	Muller et al.
4,065,263	A	12/1977	Woodbridge et al.	4,746,607	A	5/1988	Mura et al.
4,077,861	A	3/1978	Lauer	4,750,496	A	6/1988	Reinhart et al.
4,123,701	A	10/1978	Josefsen et al.	4,759,828	A	7/1988	Young et al.
4,127,448	A	11/1978	Schick et al.	4,795,542	A	1/1989	Ross et al.
4,137,495	A	1/1979	Brown	4,797,256	A	1/1989	Watlington, IV
4,184,936	A	1/1980	Paul et al.	4,805,624	A	2/1989	Yao et al.
4,214,968	A	7/1980	Battaglia et al.	4,806,311	A	2/1989	Greenquist
4,217,196	A	8/1980	Huch	4,806,312	A	2/1989	Greenquist
4,224,125	A	9/1980	Nakamura et al.	4,810,203	A	3/1989	Komatsu
4,225,410	A	9/1980	Pace et al.	4,816,224	A	3/1989	Vogel et al.
4,229,426	A	10/1980	Haagensen, Jr.	4,820,399	A	4/1989	Senda et al.
4,230,537	A	10/1980	Delente et al.	4,820,636	A	4/1989	Hill et al.
4,233,029	A	11/1980	Columbus	4,830,959	A	5/1989	McNeil et al.
4,260,680	A	4/1981	Muramatsu et al.	4,832,814	A	5/1989	Root
4,263,343	A	4/1981	Kim	4,834,234	A	5/1989	Sacherer et al.
4,265,250	A	5/1981	Parker	4,849,330	A	7/1989	Humphries et al.
4,273,639	A	6/1981	Gottermeier	4,854,153	A	8/1989	Miyagawa et al.
4,297,184	A	10/1981	Dyer	4,865,873	A	9/1989	Cole, Jr. et al.
4,297,569	A	10/1981	Flies	4,877,580	A	10/1989	Aronowitz et al.
4,301,412	A	11/1981	Hill et al.	4,890,926	A	1/1990	Dosmann et al.
4,303,887	A	12/1981	Hill et al.	4,894,137	A	1/1990	Takizawa et al.
4,304,853	A	12/1981	Jozefonvicz et al.	4,897,162	A	1/1990	Lewandowski et al.
4,323,536	A	4/1982	Columbus	4,919,770	A	4/1990	Preidel et al.
4,329,642	A	5/1982	Luthi et al.	4,927,516	A	5/1990	Yamaqucji et al.
4,366,033	A	12/1982	Richter et al.	4,929,330	A	5/1990	Osaka et al.
4,376,689	A	3/1983	Nakamura et al.	4,929,545	A	5/1990	Freitage
4,381,775	A	5/1983	Nose et al.	4,935,105	A	6/1990	Churchouse
4,396,464	A	8/1983	Giner et al.	4,935,106	A	6/1990	Liston et al.
4,402,940	A	9/1983	Nose et al.	4,936,346	A	6/1990	Kugler
4,403,984	A	9/1983	Ash et al.	4,938,860	A	7/1990	Wogoman
4,407,290	A	10/1983	Wiber	4,940,945	A	7/1990	Littlejohn et al.
4,407,959	A	10/1983	Tsuji et al.	4,954,087	A	9/1990	Lauks et al.
4,413,407	A	11/1983	Columbus	4,956,275	A	9/1990	Zuk et al.
4,420,564	A	12/1983	Tsuji et al.	4,963,814	A	10/1990	Parks et al.
4,431,004	A	2/1984	Bessman et al.	4,970,145	A	11/1990	Bennetto et al.
4,436,094	A	3/1984	Cerami	4,975,647	A	12/1990	Downer et al.
4,440,175	A	4/1984	Wilkins	4,976,724	A	12/1990	Nieto
4,473,457	A	9/1984	Columbus	4,999,582	A	3/1991	Parks et al.
4,476,149	A	10/1984	Poppe et al.	4,999,632	A	3/1991	Parks
4,477,314	A	10/1984	Richter et al.	5,018,164	A	5/1991	Brewer et al.
4,477,575	A	10/1984	Vogel et al.	5,019,974	A	5/1991	Beckers
4,490,216	A	12/1984	McConnell	5,028,542	A	7/1991	Kennamer et al.
4,499,423	A	2/1985	Matthiessen	5,035,862	A	7/1991	Dietze et al.
4,502,938	A	3/1985	Covington et al.	5,039,618	A	8/1991	Stone
4,517,291	A	5/1985	Seago	5,046,618	A	9/1991	Wood
4,545,382	A	10/1985	Higgins et al.	5,049,487	A	9/1991	Phillips et al.
4,547,735	A	10/1985	Kiesewetter et al.	5,057,447	A	10/1991	Paterson et al.
4,552,458	A	11/1985	Lowne	5,059,199	A	10/1991	Okada et al.
4,561,944	A	12/1985	Sasaki et al.	5,059,394	A	10/1991	Phillips et al.
4,571,292	A	2/1986	Liu et al.	5,066,372	A	11/1991	Weetall
4,572,899	A	2/1986	Walker et al.	5,075,077	A	12/1991	Durley, III et al.
4,578,716	A	3/1986	Van Rijckevorsel et al.	5,096,669	A	3/1992	Lauks et al.
4,579,893	A	4/1986	Wang et al.	5,096,671	A	3/1992	Kane et al.
4,582,684	A	4/1986	Vogel et al.	5,108,564	A	4/1992	Szuminsky et al.
4,591,550	A	5/1986	Hafeman et al.	5,108,819	A	4/1992	Heller et al.
				5,112,455	A	5/1992	Cozzette et al.
				5,112,758	A	5/1992	Fellman et al.
				5,118,183	A	6/1992	Cargill et al.
				5,120,420	A	6/1992	Nankai et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

5,120,421 A	6/1992	Glass et al.	5,426,032 A	6/1995	Phillips et al.
5,122,244 A	6/1992	Hoenes et al.	5,427,912 A	6/1995	Brown et al.
5,128,015 A	7/1992	Szuminsky et al.	5,429,735 A	7/1995	Johnson et al.
5,140,176 A	8/1992	Okino	5,437,772 A	8/1995	DeCastro et al.
5,141,850 A	8/1992	Cole et al.	5,437,999 A	8/1995	Diebold et al.
5,141,868 A	8/1992	Shanks et al.	5,438,271 A	8/1995	White et al.
5,143,694 A	9/1992	Schafer et al.	5,439,826 A	8/1995	Kontorovich
5,155,628 A	10/1992	Dosmann	5,445,967 A	8/1995	Deuter
5,179,005 A	1/1993	Phillips et al.	5,447,837 A	9/1995	Urnovitz
5,179,288 A	1/1993	Miffitt et al.	5,449,898 A	9/1995	Dosmann
5,182,707 A	1/1993	Cooper et al.	5,453,360 A	9/1995	Yu
5,187,100 A	2/1993	Matzinger et al.	5,468,366 A	11/1995	Wegner et al.
5,192,415 A	3/1993	Yosioka et al.	5,469,846 A	11/1995	Khan
5,202,261 A	4/1993	Musho et al.	5,470,533 A	11/1995	Shindo et al.
5,206,147 A	4/1993	Hoenes	5,477,326 A	12/1995	Dosmann
5,217,594 A	6/1993	Henkens et al.	5,489,414 A	2/1996	Schreiber et al.
5,220,920 A	6/1993	Gharib	5,494,638 A	2/1996	Gullick
5,223,117 A	6/1993	Wrighton et al.	5,500,350 A	3/1996	Baker et al.
5,229,282 A	7/1993	Yoshioka et al.	5,502,396 A	3/1996	Desarzens et al.
5,232,516 A	8/1993	Hed	5,504,011 A	4/1996	Gavin et al.
5,232,667 A	8/1993	Hieb et al.	5,508,171 A	4/1996	Walling et al.
5,232,668 A	8/1993	Grante et al.	5,508,200 A	4/1996	Tiffany et al.
5,234,813 A	8/1993	McGreenhan et al.	5,508,203 A	4/1996	Fuller et al.
5,243,516 A	9/1993	White	5,509,410 A	4/1996	Hill et al.
5,246,858 A	9/1993	Arbuckle et al.	5,512,159 A	4/1996	Yoshioka et al.
5,250,439 A	10/1993	Musho et al.	5,515,847 A	5/1996	Braig et al.
5,261,411 A	11/1993	Hughes et al.	5,518,689 A	5/1996	Dosmann et al.
5,262,035 A	11/1993	Gregg et al.	5,520,786 A	5/1996	Bloczynski et al.
5,264,103 A	11/1993	Yoshioka et al.	5,526,111 A	6/1996	Collins et al.
5,264,104 A	11/1993	Gregg et al.	5,526,120 A	6/1996	Jina et al.
5,266,179 A	11/1993	Nanki et al.	5,526,808 A	6/1996	Kaminsky
5,269,891 A	12/1993	Colin	5,532,128 A	7/1996	Eggers et al.
5,279,294 A	1/1994	Anderson et al.	5,545,519 A	8/1996	Vadagama et al.
5,281,395 A	1/1994	Markart et al.	5,552,116 A	9/1996	Yokota et al.
5,282,950 A	2/1994	Dietze et al.	5,554,531 A	9/1996	Zweig
5,284,770 A	2/1994	Adrain et al.	5,556,789 A	9/1996	Goerlach-Graw et al.
5,286,362 A	2/1994	Hoenes et al.	5,563,031 A	10/1996	Yu
5,288,387 A	2/1994	Ito et al.	5,563,042 A	10/1996	Phillips et al.
5,288,636 A	2/1994	Pollmann et al.	5,569,591 A	10/1996	Kell et al.
5,304,468 A	4/1994	Phillips et al.	5,569,608 A	10/1996	Sommer
5,306,623 A	4/1994	Kiser et al.	5,572,159 A	11/1996	McFarland
5,311,426 A	5/1994	Donohue et al.	5,575,403 A	11/1996	Charlton et al.
5,312,590 A	5/1994	Gunasingham	5,575,895 A	11/1996	Ikeda et al.
5,320,725 A	6/1994	Gregg et al.	5,576,073 A	11/1996	Kickelhain
5,320,732 A	6/1994	Nankai et al.	5,580,794 A	12/1996	Allen
5,321,492 A	6/1994	Detwiler et al.	5,582,697 A	12/1996	Ikeda et al.
5,332,479 A	7/1994	Uenoyama et al.	5,589,045 A	12/1996	Hyodo
5,334,296 A	8/1994	Henkens et al.	5,589,326 A	12/1996	Deng et al.
5,344,754 A	9/1994	Zewing	5,593,390 A	1/1997	Castellano et al.
5,352,351 A	10/1994	White et al.	5,593,739 A	1/1997	Kickelhain
5,353,351 A	10/1994	Bartoli et al.	5,594,906 A	1/1997	Holmes, II et al.
5,354,447 A	10/1994	Uenoyama et al.	5,597,532 A	1/1997	Connolly
5,356,786 A	10/1994	Heller et al.	5,603,820 A	2/1997	Malinski et al.
5,361,314 A	11/1994	Kopelman et al.	5,604,110 A	2/1997	Baker et al.
5,366,609 A	11/1994	White et al.	5,605,662 A	2/1997	Heller et al.
5,368,707 A	11/1994	Henkens et al.	5,605,837 A	2/1997	Karimi et al.
5,371,687 A	12/1994	Holmes, II et al.	5,611,909 A	3/1997	Studer
5,376,254 A	12/1994	Fisher	5,611,999 A	3/1997	Dosmann et al.
5,379,214 A	1/1995	Arbuckle et al.	5,620,579 A	4/1997	Genshaw et al.
5,384,028 A	1/1995	Ito	5,620,863 A	4/1997	Tomasco et al.
5,385,846 A	1/1995	Kuhn et al.	5,620,890 A	4/1997	Kamps-Holtzappple et al.
5,389,215 A	2/1995	Horiuchi et al.	5,627,922 A	5/1997	Kopelman et al.
5,391,272 A	2/1995	O'Daly et al.	5,628,890 A	5/1997	Carter et al.
5,393,903 A	2/1995	Gratzel et al.	5,630,986 A	5/1997	Charlton et al.
5,395,504 A	3/1995	Saurer et al.	5,635,362 A	6/1997	Levine et al.
5,403,462 A	4/1995	Lev et al.	5,635,364 A	6/1997	Clark et al.
5,405,511 A	4/1995	White et al.	5,639,671 A	6/1997	Bogart et al.
5,410,059 A	4/1995	Fraser et al.	5,642,734 A	7/1997	Ruben et al.
5,410,474 A	4/1995	Fox	5,644,501 A	7/1997	Lin et al.
5,411,647 A	5/1995	Johnson et al.	5,645,798 A	7/1997	Schreiber et al.
5,413,690 A	5/1995	Kost et al.	5,650,061 A	7/1997	Kuhr et al.
5,413,764 A	5/1995	Haar	5,650,062 A	7/1997	Ikeda et al.
5,418,142 A	5/1995	Kiser et al.	5,653,863 A	8/1997	Genshaw et al.
5,421,189 A	6/1995	Dussault	5,654,178 A	8/1997	Fitzpatrick et al.
5,424,035 A	6/1995	Hones et al.	5,656,502 A	8/1997	Mackay et al.
			5,658,443 A	8/1997	Yamamoto et al.
			5,658,802 A	8/1997	Hayes et al.
			5,660,791 A	8/1997	Brenneman et al.
			5,665,215 A	9/1997	Bussmann et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

5,670,031	A	9/1997	Hintsche et al.	6,045,567	A	4/2000	Taylor et al.
5,682,884	A	11/1997	Hill et al.	6,054,039	A	4/2000	Shieh
5,686,659	A	11/1997	Neel et al.	6,061,128	A	5/2000	Zweig et al.
5,691,486	A	11/1997	Behringer et al.	6,069,011	A	5/2000	Riedel
5,691,633	A	11/1997	Liu et al.	6,071,391	A	6/2000	Gotoh et al.
5,695,623	A	12/1997	Michel et al.	6,087,182	A	7/2000	Jeng et al.
5,695,947	A	12/1997	Guo et al.	6,091,975	A	7/2000	Daddona et al.
5,698,083	A	12/1997	Glass	6,102,872	A	8/2000	Doneen et al.
5,700,695	A	12/1997	Yassinzadeh et al.	6,103,033	A	8/2000	Say et al.
5,701,181	A	12/1997	Boiarski et al.	6,103,509	A	8/2000	Sode
5,704,354	A	1/1998	Preidel et al.	6,110,354	A	8/2000	Saban et al.
5,708,247	A	1/1998	McAleer et al.	6,120,676	A	9/2000	Heller et al.
5,710,011	A	1/1998	Forrow et al.	6,121,009	A	9/2000	Heller et al.
5,710,622	A	1/1998	Neel et al.	6,121,050	A	9/2000	Han
5,719,667	A	2/1998	Miers	6,126,609	A	10/2000	Keith et al.
5,720,862	A	2/1998	Hamamoto et al.	6,128,519	A	10/2000	Say
5,723,284	A	3/1998	Ye	6,129,823	A	10/2000	Hughes et al.
5,723,345	A	3/1998	Yamauchi et al.	6,134,461	A	10/2000	Say et al.
5,727,548	A	3/1998	Hill et al.	6,136,549	A	10/2000	Feistel
5,728,074	A	3/1998	Castellano et al.	6,136,610	A	10/2000	Polito et al.
5,745,308	A	4/1998	Spangenberg et al.	6,143,164	A	11/2000	Heller et al.
5,748,002	A	5/1998	Scott et al.	6,143,247	A	11/2000	Sheppard, Jr. et al.
5,755,953	A	5/1998	Henning et al.	6,144,869	A	11/2000	Berner et al.
5,757,666	A	5/1998	Schreiber et al.	6,150,124	A	11/2000	Riedel
5,759,364	A	6/1998	Charlton et al.	6,153,069	A	11/2000	Pottgen et al.
5,759,794	A	6/1998	Levine et al.	6,156,051	A	12/2000	Schrage
5,762,770	A	6/1998	Pritchard et al.	6,156,173	A	12/2000	Gotoh et al.
5,776,710	A	7/1998	Levine et al.	6,156,673	A	12/2000	Hintermaier et al.
5,780,304	A	7/1998	Matzinger et al.	6,157,442	A	12/2000	Raskas
5,786,584	A	7/1998	Button et al.	6,157,472	A	12/2000	Eum et al.
5,788,833	A	8/1998	Lewis et al.	6,159,745	A	12/2000	Roberts et al.
5,789,255	A	8/1998	Yu	6,162,611	A	12/2000	Heller et al.
5,792,668	A	8/1998	Fuller et al.	6,162,639	A	12/2000	Douglas
5,798,031	A	8/1998	Charlton et al.	6,168,563	B1	1/2001	Brown
5,801,057	A	9/1998	Smart et al.	6,168,957	B1	1/2001	Matzinger et al.
5,807,375	A	9/1998	Gross et al.	6,170,318	B1	1/2001	Lewis
5,820,551	A	10/1998	Hill et al.	6,174,420	B1	1/2001	Hodges et al.
5,820,662	A	10/1998	Kubo et al.	6,175,752	B1	1/2001	Say et al.
5,832,921	A	11/1998	Lennert et al.	6,176,988	B1	1/2001	Kessler
5,834,217	A	11/1998	Levine et al.	6,179,979	B1	1/2001	Hodges et al.
5,837,546	A	11/1998	Allen et al.	6,180,062	B1	1/2001	Naka et al.
5,843,691	A	12/1998	Douglas et al.	6,181,417	B1	1/2001	Dosmann
5,843,692	A	12/1998	Phillips et al.	6,193,873	B1	2/2001	Oharra et al.
5,846,794	A	12/1998	Delobbeau et al.	6,197,040	B1	3/2001	LeVaughn et al.
5,849,174	A	12/1998	Sanghera et al.	6,200,773	B1	3/2001	Ouyang et al.
5,856,195	A	1/1999	Charlton et al.	6,201,607	B1	3/2001	Roth et al.
5,863,400	A	1/1999	Drummond et al.	6,203,952	B1	3/2001	O'Brian et al.
5,873,990	A	2/1999	Wojciechowski et al.	6,206,282	B1	3/2001	Hayes, Sr. et al.
5,874,046	A	2/1999	Megerle et al.	6,206,292	B1	3/2001	Roberts et al.
5,883,378	A	3/1999	Irish et al.	6,207,000	B1	3/2001	Schwobel et al.
5,885,839	A	3/1999	Lingane et al.	6,212,417	B1	4/2001	Ikeda et al.
5,890,489	A	4/1999	Elden	6,218,571	B1	4/2001	Zhena et al.
5,904,898	A	5/1999	Market	6,225,078	B1	5/2001	Ikeda et al.
5,911,872	A	6/1999	Lewis et al.	6,226,081	B1	5/2001	Fantone et al.
5,916,156	A	6/1999	Hildenbrand et al.	6,233,471	B1	5/2001	Berner et al.
5,921,925	A	7/1999	Cartmell et al.	6,241,862	B1	6/2001	McAleer et al.
5,922,530	A	7/1999	Yu	6,246,862	B1	6/2001	Grivas et al.
5,922,591	A	7/1999	Anderson et al.	6,246,966	B1	6/2001	Perry
5,925,021	A	7/1999	Castellano et al.	6,251,260	B1	6/2001	Heller et al.
RE36,268	E	8/1999	Szuminsky et al.	6,258,229	B1	7/2001	Winarta et al.
5,942,102	A	8/1999	Hodges et al.	6,259,937	B1	7/2001	Schulman et al.
5,945,341	A	8/1999	Howard, III	6,261,519	B1	7/2001	Harding et al.
5,948,289	A	9/1999	Noda et al.	6,262,749	B1	7/2001	Finger et al.
5,958,199	A	9/1999	Miyamoto et al.	6,268,162	B1	7/2001	Phillips et al.
5,965,380	A	10/1999	Heller et al.	6,270,637	B1	8/2001	Crismore et al.
5,968,760	A	10/1999	Phillips et al.	6,271,044	B1	8/2001	Ballerstadt et al.
5,971,923	A	10/1999	Finger	6,272,262	B1	8/2001	Kopelman et al.
5,989,917	A	11/1999	McAleer et al.	6,272,364	B1	8/2001	Kurnok
6,001,239	A	12/1999	Douglas et al.	6,275,717	B1	8/2001	Gross et al.
6,004,441	A	12/1999	Fujiwara et al.	6,277,641	B1	8/2001	Yager
6,004,442	A	12/1999	Choulga et al.	6,281,006	B1	8/2001	Heller et al.
6,013,170	A	1/2000	Meade	6,284,125	B1	9/2001	Hodges et al.
6,033,866	A	3/2000	Guo et al.	6,284,550	B1	9/2001	Carroll et al.
6,042,714	A	3/2000	Lin et al.	6,287,451	B1	9/2001	Winarta et al.
6,044,285	A	3/2000	Chaiken et al.	6,287,595	B1	9/2001	Loewy et al.
				6,294,062	B1	9/2001	Buck et al.
				6,294,281	B1	9/2001	Heller
				6,294,787	B1	9/2001	Schieferdecker et al.
				6,295,506	B1	9/2001	Heinonen et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

6,297,697 B2	10/2001	Delano et al.	6,576,101 B1	6/2003	Heller et al.
6,299,757 B1	10/2001	Feldman et al.	6,576,416 B2	6/2003	Haviland et al.
6,300,123 B1	10/2001	Vadgama et al.	6,576,461 B2	6/2003	Heller et al.
6,300,961 B1	10/2001	Finger et al.	6,579,690 B1	6/2003	Bonnecaze
6,309,526 B1	10/2001	Fujiwara et al.	6,591,125 B1	7/2003	Buse et al.
6,315,951 B1	11/2001	Markart	6,592,744 B1	7/2003	Hodges et al.
6,316,264 B1	11/2001	Corey et al.	6,592,745 B1	7/2003	Feldmen et al.
6,326,160 B1	12/2001	Dunn et al.	6,594,514 B2	7/2003	Berner et al.
6,329,161 B1	12/2001	Heller et al.	6,599,407 B2	7/2003	Taniike et al.
6,330,464 B1	12/2001	Colvin, Jr. et al.	6,600,997 B2	7/2003	Deweese et al.
6,335,203 B1	1/2002	Patel et al.	6,605,200 B1	8/2003	Mao et al.
6,338,790 B1	1/2002	Feldman et al.	6,605,201 B1	8/2003	Mao et al.
6,340,428 B1	1/2002	Ikeada et al.	6,607,658 B1	8/2003	Heller et al.
6,342,364 B1	1/2002	Watanabe et al.	6,616,819 B1	9/2003	Liamos et al.
6,344,133 B1	2/2002	Formica et al.	6,618,934 B1	9/2003	Feldmen et al.
6,349,230 B1	2/2002	Kawanaka et al.	6,623,501 B2	9/2003	Heller et al.
6,358,752 B1	3/2002	Durst et al.	6,627,057 B1	9/2003	Bullar et al.
6,377,896 B1	4/2002	Sato et al.	6,632,349 B1	10/2003	Hodges et al.
6,379,513 B1	4/2002	Chambers et al.	6,636,652 B1	10/2003	Kopelman et al.
6,389,891 B1	5/2002	D'Angelico et al.	6,638,415 B1	10/2003	Hodges et al.
6,391,558 B1	5/2002	Henkens et al.	6,638,716 B2	10/2003	Heller et al.
6,391,645 B1	5/2002	Huang et al.	6,645,359 B1	11/2003	Bhullar et al.
6,394,952 B1	5/2002	Anderson et al.	6,645,368 B1	11/2003	Beaty et al.
6,395,227 B1	5/2002	Kiser et al.	6,654,625 B1	11/2003	Say et al.
6,399,258 B2	6/2002	O'Brien et al.	6,656,702 B1	12/2003	Yugawa et al.
6,401,532 B2	6/2002	Lubbers	6,676,816 B2	1/2004	Mao et al.
6,413,398 B1	7/2002	Gerhardt et al.	6,676,995 B2	1/2004	Dick et al.
6,413,411 B1	7/2002	Pottgen et al.	6,689,265 B2	2/2004	Heller et al.
6,414,213 B2	7/2002	Ohmori et al.	6,689,411 B2	2/2004	Dick et al.
6,414,395 B1	7/2002	Ookuma et al.	6,690,836 B2	2/2004	Natarajan et al.
6,414,410 B1	7/2002	Nakamura et al.	6,699,384 B1	3/2004	Lin et al.
6,420,128 B1	7/2002	Ouyang et al.	6,749,740 B2	6/2004	Liamos et al.
6,444,115 B1	9/2002	Hodges et al.	6,767,441 B1	7/2004	Cai et al.
6,447,657 B1	9/2002	Bhullar et al.	6,790,341 B1	9/2004	Saba et al.
6,454,921 B1	9/2002	Hodges et al.	6,824,669 B1	11/2004	Choong et al.
6,461,496 B1	10/2002	Feldman et al.	6,824,670 B2	11/2004	Tokunaga et al.
6,475,372 B1	11/2002	Ohara et al.	6,841,052 B2	1/2005	Musho et al.
6,484,046 B1	11/2002	Say et al.	6,890,421 B2	5/2005	Oharra et al.
6,485,923 B1	11/2002	Yani et al.	6,893,545 B2	5/2005	Gotoh et al.
6,488,827 B1	12/2002	Shartle	6,942,518 B2	9/2005	Liamos et al.
6,489,133 B2	12/2002	Phillips et al.	7,018,843 B2	3/2006	Heller
6,491,803 B1	12/2002	Shen et al.	7,122,111 B2	10/2006	Tokunaga et al.
6,491,870 B2	12/2002	Patel et al.	7,132,041 B2	11/2006	Deng et al.
6,501,976 B1	12/2002	Sohrab	7,276,146 B2	10/2007	Wilsey
6,503,381 B1	1/2003	Gotoh et al.	7,351,323 B2	4/2008	Iketaki et al.
6,512,986 B1	1/2003	Harmon	8,026,104 B2	9/2011	Wu et al.
6,514,718 B2	2/2003	Heller et al.	8,088,272 B2	1/2012	Deng
6,521,110 B1	2/2003	Hodges et al.	8,101,062 B2	1/2012	Deng
6,521,182 B1	2/2003	Shartle et al.	8,147,674 B2	4/2012	Wu
6,525,330 B2	2/2003	Paolini et al.	8,234,076 B2	7/2012	Carpenter et al.
6,525,549 B1	2/2003	Poellmann	8,262,899 B2	9/2012	Wu
6,526,298 B1	2/2003	Khalil et al.	8,287,717 B2	10/2012	Wu
6,531,040 B2	3/2003	Musho et al.	8,404,100 B2	3/2013	Wu
6,531,239 B2	3/2003	Heller	8,425,757 B2	4/2013	Wu et al.
6,531,322 B1	3/2003	Jurik et al.	8,470,604 B2	6/2013	Wu et al.
6,535,753 B1	3/2003	Raskas	2001/0000129 A1	4/2001	Raskas
6,537,498 B1	3/2003	Lewis et al.	2001/0006149 A1	7/2001	Taniike et al.
6,538,735 B1	3/2003	Duebendorfer et al.	2001/0017269 A1	8/2001	Heller et al.
6,540,890 B1	4/2003	Bhullar et al.	2001/0042683 A1	11/2001	Musho et al.
6,540,891 B1	4/2003	Stewart et al.	2001/0052470 A1	12/2001	Hodges et al.
6,541,266 B2	4/2003	Modzelewski et al.	2002/0004106 A1	1/2002	Leddy et al.
6,544,474 B2	4/2003	Douglas et al.	2002/0012821 A1	1/2002	Leddy et al.
6,549,796 B2	4/2003	Sohrab	2002/0053523 A1	5/2002	Liamos et al.
6,551,494 B1	4/2003	Feldman et al.	2002/0079219 A1	6/2002	Zhao et al.
6,555,061 B1	4/2003	Leong et al.	2002/0081588 A1	6/2002	De Lumley-Woodyear et al.
6,558,528 B1	5/2003	Matzinger	2002/0084196 A1	7/2002	Liamos et al.
6,558,529 B1	5/2003	McVey et al.	2002/0125146 A1	9/2002	Chan et al.
6,560,471 B1	5/2003	Heller et al.	2002/0139692 A1	10/2002	Tokunaga et al.
6,562,625 B2	5/2003	Modzelewski et al.	2002/0157967 A1	10/2002	Ling et al.
6,565,509 B1	5/2003	Haller et al.	2002/0180446 A1	12/2002	Kuhr et al.
6,565,738 B1	5/2003	Henning et al.	2002/0185375 A1	12/2002	Wogoman
6,570,390 B2	5/2003	Hirayama et al.	2003/0064525 A1	4/2003	Liess
6,571,651 B1	6/2003	Hodges	2003/0113933 A1	6/2003	Jansson et al.
6,572,822 B2	6/2003	Jurki et al.	2003/0119208 A1	6/2003	Yoon et al.
6,574,425 B1	6/2003	Weiss et al.	2003/0136673 A1	7/2003	Pilloud et al.
			2003/0146110 A1	8/2003	Karinka et al.
			2003/0148169 A1	8/2003	Willner et al.
			2003/0149348 A1	8/2003	Raskas
			2003/0159927 A1	8/2003	Lewis et al.

(56)	References Cited			EP	164180	12/1985	
				EP	255291	2/1986	
	U.S. PATENT DOCUMENTS			EP	206218	12/1986	
				EP	213343	3/1987	
2003/0175737	A1	9/2003	Schulien et al.	EP	215678	3/1987	
2003/0175841	A1 *	9/2003	Watanabe C12Q 1/001	EP	230472	8/1987	
			435/14	EP	241309	10/1987	
2003/0176183	A1	9/2003	Drucker et al.	EP	287883	10/1988	
2003/0178322	A1	9/2003	Bolon et al.	EP	330517	2/1989	
2003/0199744	A1	10/2003	Buse et al.	EP	354441	2/1990	
2003/0201194	A1	10/2003	Heller et al.	EP	359531	3/1990	
2003/0205465	A1	11/2003	Feng et al.	EP	359831	3/1990	
2003/0209450	A1	11/2003	McVey et al.	EP	383322	8/1990	
2004/0005716	A9	1/2004	Beaty et al.	EP	417796	3/1991	
2004/0007461	A1	1/2004	Edelbrock	EP	470649	2/1992	
2004/0026253	A1	2/2004	Leddy et al.	EP	471986	2/1992	
2004/0033165	A1	2/2004	Lewis et al.	EP	537761	4/1993	
2004/0040840	A1	3/2004	Mao et al.	EP	546536	6/1993	
2004/0045821	A1	3/2004	Cui et al.	EP	546796	6/1993	
2004/0054267	A1	3/2004	Feldman et al.	EP	0628810	12/1994	
2004/0055898	A1	3/2004	Heller et al.	EP	636880	2/1995	
2004/0060818	A1	4/2004	Feldmen et al.	EP	640832	3/1995	
2004/0061841	A1	4/2004	Black et al.	EP	651250	5/1995	
2004/0074772	A1	4/2004	Kumar et al.	EP	186286	7/1996	
2004/0079653	A1	4/2004	Karinka et al.	EP	732406	9/1996	
2004/0099531	A1	5/2004	Srinivasan et al.	EP	732590	9/1996	
2004/0118682	A1	6/2004	Murray et al.	EP	0741186	11/1996	
2004/0149577	A1	8/2004	Kumar et al.	EP	0762112	3/1997	
2004/0157337	A1	8/2004	Burke et al.	EP	800086	10/1997	
2004/0157338	A1	8/2004	Burke et al.	EP	837320	4/1998	
2004/0157339	A1	8/2004	Burke et al.	EP	840122	5/1998	
2004/0180444	A1	9/2004	Rannikko et al.	EP	851224	7/1998	
2004/0224137	A1	11/2004	Rogalska et al.	EP	859230	8/1998	
2004/0225230	A1	11/2004	Liamos et al.	EP	878708	11/1998	
2004/0245121	A1	12/2004	Nagakawa et al.	EP	878713	11/1998	
2004/0253367	A1	12/2004	Wogoman	EP	887421	12/1998	
2004/0256248	A1	12/2004	Burke et al.	EP	894509	2/1999	
2004/0259180	A1	12/2004	Burke et al.	EP	942278	9/1999	
2004/0260511	A1	12/2004	Burke et al.	EP	964059	12/1999	
2005/0009126	A1	1/2005	Andrews et al.	EP	1156324	11/2002	
2005/0049473	A1	3/2005	Desai et al.	EP	0 800 086	1/2003 G01N 33/96
2005/0069892	A1	3/2005	Lyengar et al.	EP	1279742	1/2003	
2005/0164322	A1	7/2005	Heller et al.	EP	1411348	4/2004	
2005/0176153	A1	8/2005	O'hara et al.	ES	2184236	1/2003	
2005/0247562	A1	11/2005	Tokunaga et al.	ES	2223185	2/2005	
2006/0063218	A1	3/2006	Bartkowiak et al.	FR	2325920	9/1976	
2006/0074564	A1	4/2006	Bartkowiak et al.	GB	2295676	6/1996	
2006/0085137	A1	4/2006	Bartkowiak et al.	JP	62209350	9/1987	
2006/0191787	A1	8/2006	Wang et al.	JP	3260739	11/1991	
2007/0074977	A1	4/2007	Guo et al.	JP	09089832	4/1997	
2007/0080073	A1	4/2007	Wu et al.	JP	11087213	3/1999	
2008/0102441	A1	5/2008	Chen et al.	JP	2120657	5/1999	
2008/0145878	A1	6/2008	Marfurt	JP	2003028826	1/2003	
2008/0149480	A1	6/2008	Bell	JP	200361650	3/2003	
2009/0014339	A1	1/2009	Beer et al.	JP	200403478	1/2004	
2009/0026094	A1	1/2009	Deng et al.	JP	2004093478	3/2004	
2012/0211361	A1	8/2012	Wu	JP	2004300328	10/2004	
2012/0298507	A1	11/2012	Wu	JP	2005147990	6/2005	
2013/0240377	A1	9/2013	Wu	WO	WO 81/01794	7/1981	
				WO	WO 82/03729	10/1982	
				WO	WO 83/00926	3/1983	
				WO	WO 86/00138	1/1986	
				WO	WO 86/02732	5/1986	
				WO	WO 90/05293	5/1990	
				WO	WO 90/05910	5/1990	
				WO	WO 92/01928	2/1992	
				WO	WO 92/07655	5/1992	
				WO	WO 92/15704	9/1992	
				WO	WO 92/15859	9/1992	
				WO	WO 92/15861	9/1992	
				WO	WO 92/15950	9/1992	
				WO	WO 92/19961	11/1992	
				WO	WO 92/22669	12/1992	
				WO	WO 93/09433	5/1993	
				WO	WO 93/21928	11/1993	
				WO	WO 95/03542	2/1995	
				WO	WO 95/07050	3/1995	
				WO	WO 95/13535	5/1995	
				WO	WO 95/13536	5/1995	
CN	1322299	10/2000					
CN	1328156	12/2001					
CN	1598564	10/2004					
DE	229500	6/1985					
DE	271179	8/1989					
DE	4003194	8/1991					
DE	4100727	7/1992					
DE	19944318891	12/1994					
DE	19824629	12/1999					
DE	69915850	1/2005					
EP	34049	8/1981					
EP	57110	8/1982					
EP	120715	10/1984					
EP	121385	10/1984					
EP	127958	12/1984					
EP	10375	12/1985					

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO	WO 95/22597	8/1995	WO	WO 01/57510	8/2001
WO	WO 96/04398	2/1996	WO	WO 01/57513	8/2001
WO	WO 96/07908	3/1996	WO	WO 01/65246	9/2001
WO	WO 96/13707	5/1996	WO	WO 01/67099	9/2001
WO	WO 96/15454	5/1996	WO	WO 02/01214	1/2002
WO	WO 96/14026	10/1996	WO	WO 02/31482	4/2002
WO	WO 96/33403	10/1996	WO	WO 02/031481	10/2002
WO	WO 97/00441	1/1997	WO	WO 02/077633	10/2002
WO	WO 97/02487	1/1997	WO	WO 03/001195	1/2003
WO	WO 97/08544	3/1997	WO	WO 03/069304	2/2003
WO	WO 97/16726	5/1997	WO	WO 03/066554	6/2003
WO	WO 97/18465	5/1997	WO	WO 03/087802	10/2003
WO	WO 97/29366	8/1997	WO	WO 2004/023128	3/2004
WO	WO 97/29847	8/1997	WO	WO 2004/040286	5/2004
WO	WO 97/30344	8/1997	WO	WO 2004/046707	6/2004
WO	WO 97/39343	10/1997	WO	WO 2004/053476	6/2004
WO	WO 97/42882	11/1997	WO	WO 2004/062801	7/2004
WO	WO 97/42888	11/1997	WO	WO 2004/113896	12/2004
WO	WO 97/45719	12/1997	WO	WO 2004/113912	12/2004
WO	WO 98/05424	2/1998	WO	WO 2004/113913	12/2004
WO	WO 98/19153	5/1998	WO	WO 2005/001462	1/2005
WO	WO 98/19159	5/1998	WO	WO 2005/001463	1/2005
WO	WO 98/29740	7/1998	WO	WO 2005/003748	1/2005
WO	WO 98/44342	10/1998	WO	WO 2005/008231	1/2005
WO	WO 98/58246	12/1998	WO	WO 2005/022143	3/2005
WO	WO 98/58250	12/1998	WO	WO 2005/040407	5/2005
WO	WO 99/22227	5/1999	WO	WO 2005/045234	5/2005
WO	WO 99/22230	5/1999	WO	WO 2005/078118	8/2005
WO	WO 99/45375	9/1999	WO	WO 2006/079797	8/2006
WO	WO 99/67628	12/1999	WO	WO 2006/110504	10/2006
WO	WO 00/16089	3/2000	OTHER PUBLICATIONS		
WO	WO 00/20626	4/2000	Hall, J.W. et al., "Automated Determination of Glucose using ENZ Glucose Oxidase and Potassium Ferrocyanide ENZ Peroxidase," Analytical Biochemistry, vol. 26, No. 1, 1968, pp. 12-17.		
WO	WO 00/20855	4/2000	PCT International Search Report dated Jun. 2, 2005, PCT/US2005/003622, 3 pages.		
WO	WO 00/29540	5/2000	Yao, et al., "A Thin-Film Glucose Electrode System with Compensation for Drift", 1989, pp. 742-744, vol. XXXV.		
WO	WO 00/57011	9/2000	Yao, et al., "The Low-Potential Approach of Glucose Sensing", 1986, pp. 139-146, vol. BME-33, No. 2.		
WO	WO 00/77523	12/2000			
WO	WO 01/03207	1/2001			
WO	WO 01/33206	5/2001			
WO	WO 01/33216	5/2001			
WO	WO 01/56771	8/2001			

* cited by examiner




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 3




FIG. 4




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B




FIG. 7




FIG. 8A




FIG. 8B

METHOD OF USING A BIOSENSOR

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a division of application Ser. No. 10/590,867 filed Aug. 24, 2006, which has been allowed; application Ser. No. 10/590,867 filed Aug. 24, 2006 is a nationalized application of Application No. PCT/US2005/03622 filed Feb. 4, 2005, which claims priority to Application No. 60/542,362 filed on Feb. 6, 2004, which are all incorporated by reference in their entireties.


FIELD OF THE INVENTION

The present invention generally relates to a biosensor, and, more particularly, to a new and improved biosensor, including an oxidizable species as an internal reference and methods of use of the biosensor, for determining the presence or amount of a substance in a sample.




DESCRIPTION OF THE PRIOR ART

The quantitative determination of analytes in body fluids is of great importance in the diagnoses and maintenance of certain physiological abnormalities. For example lactate, cholesterol and bilirubin should be monitored in certain individuals. In particular, the determination of glucose in body fluids is of great importance to diabetic individuals who must frequently check the level of glucose in their body fluids as a means of regulating the glucose intake in their diets. While the remainder of the disclosure herein will be directed towards the determination of glucose, it is to be understood that the new and improved sensor element and method of use of this invention can be used for the determination of other analytes upon selection of the appropriate enzyme.

Methods for determining analyte concentration in fluids can be based on the electrochemical reaction between the analyte and an enzyme specific to the analyte and a mediator which maintains the enzyme in its initial oxidation state. Suitable redox enzymes include oxidases, dehydrogenases, catalase and peroxidase. For example, in the case where glucose is the analyte, the reaction with glucose oxidase and oxygen is represented by equation:



In the initial step of the reaction represented by equation (A), glucose present in the test sample converts the enzyme (E_{ox}), such as the oxidized flavin adenine dinucleotide (FAD) center of the enzyme into its reduced form (E_{red}), for example, (FADH₂). Because these redox centers are essentially electrically insulated within the enzyme molecule, direct electron transfer to the surface of a conventional electrode does not occur to any measurable degree in the absence of an unacceptably high cell voltage. An improvement to this system involves the use of a nonphysiological redox coupling between the electrode and the enzyme to shuttle electrons between the (FADH₂) and the electrode. This is represented by the following scheme in which the redox coupler, typically referred to as a mediator, is represented by M:



In the scheme, GO(FAD) represents the oxidized form of glucose oxidase and GO(FADH₂) indicates its reduced form. The mediating species $\text{M}_{ox}/\text{M}_{red}$ shuttles electrons from the reduced enzyme to the electrode thereby oxidizing the enzyme causing its regeneration in situ.

U.S. Pat. Nos. 5,620,579 and 5,653,863 issued to Genshaw et al., and assigned to the present assignee, disclose apparatus and method for determining the concentration of an analyte in a fluid test sample by applying the fluid test sample to the surface of a working electrode, which is electrochemically connected to a counter electrode, and which surface bears a composition comprising an enzyme specific for the analyte. A mediator is reduced in response to a reaction between the analyte and the enzyme. An oxidizing potential is applied between the electrodes to return at least a portion of the mediator back to its oxidized form before determining the concentration of the analyte to thereby increase the accuracy of the analyte determination. Following this initially applied potential, the circuit is switched to an open circuit or to a potential that substantially reduces the current to minimize the rate of electrochemical potential at the working electrode. A second potential is applied between the electrodes and the current generated in the fluid test sample is measured to determine analyte concentration. Optionally, the accuracy of the analyte determination is further enhanced algorithmically.

SUMMARY OF THE INVENTION

Important aspects of the present invention are to provide a new and improved biosensor for determining the presence or amount of a substance in a sample including an oxidizable species as an internal reference and method of use of the biosensor.

In brief, a biosensor for determining the presence or amount of a substance in a sample and methods of use of the biosensor are provided. The biosensor for receiving a user sample to be analyzed includes a mixture for electrochemical reaction with an analyte. The mixture includes an enzyme, a mediator and an oxidizable species as an internal reference.

The internal reference is defined as the oxidizable species which in one embodiment can be further defined as the reduced form of a reversible redox couple that has an equal or higher redox potential than that of the mediator. The internal reference acts to increase the response current additively for operation potentials that oxidize both species and in the case where glucose is the analyte, a total response current is represented by:

$$I_{total} = I_{int-ref} + I_{glucose}$$

$$I_{int-ref} \propto (\text{internal reference}) \text{ and } I_{glucose} \propto (\text{glucose});$$

Where $I_{int-ref}$ is the portion of the total response current due to the internal reference, while $I_{glucose}$ is due to the oxidation of mediator proportional to the glucose concentration.

In accordance with features of the invention, the internal reference can be either the same mediator species or an oxidizable species with a higher redox potential than the mediator. Thus for biosensors with a low operation potential oxidizing only the mediator, the current $I_{int-ref}$ will be zero. However, for biosensors with a higher operation potential that oxidizes both species, the total response current will be the sum of the portion due to internal reference and that due to glucose. Since the internal reference concentration is fixed, the calibration slope of the sensor will only depend on the sensor response for glucose while the intercept will depend on the added amount of the internal reference. In another

words, the internal reference will only offset the intercept and will not change the calibration slope. Thus, the concept of internal reference provides new and different ways to make glucose biosensors.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention together with the above and other objects and advantages may best be understood from the following detailed description of the preferred embodiments of the invention illustrated in the drawings, wherein:

FIG. 1A is a block diagram representation of biosensor meter including a biosensor having an internal reference in accordance with the present invention;

FIGS. 1B, 1C, and 1D are diagrams respectively illustrating operational methods for use with the biosensor of FIG. 1 of the invention;

FIGS. 2A, 2B, and 2C are charts showing three cyclic voltammograms of MLB based glucose biosensors with ferrocyanide as the internal reference the biosensor of FIG. 1 of the invention in whole blood samples of 0 mg/dL glucose;

FIG. 3 is a chart illustrating a linear response of the biosensor of FIG. 1 of the invention at different voltage operating potentials;

FIG. 4 is a chart illustrating effect of the added internal reference to the overall voltammetric current using biosensors of FIG. 1 of the invention with 10% printed ferricyanide as the counter electrode;

FIGS. 5A and 5B are charts illustrating linear response and increased intercept with increasing internal reference of MLB based biosensors of FIG. 1 of the invention with Ag/AgCl as the counter electrode;

FIGS. 6A and 6B are charts illustrating linear response and increased intercept with increasing internal reference of MLB based biosensors of FIG. 1 of the invention with 10% ferricyanide as the counter electrode;

FIG. 7 is a chart illustrating linear relationship of the calibration intercept with increasing internal reference of DEX biosensors of FIG. 1 of the invention with 10% ferricyanide as the counter electrode; and

FIGS. 8A and 8B are charts illustrating the ratio of signal to reference results from flow-injection-analysis (FIA) of the residual ferrocyanide from a control reagent ink and the reagent ink with 0.1% ferrocyanide added to the reagent mixture of 20% ferricyanide of a biosensor of FIG. 1 of the invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention relates to an electrochemical biosensor for determining the presence or amount of a substance in a sample. The biosensor includes sensor strips containing a working electrode and a counter electrode, each of which is at least partially covered with, for example, a separate reagent layer. The reagent layer on the working electrode includes, for example, an enzyme that interacts with an analyte through an oxidation-reduction reaction and also includes a mediator that is the oxidized form of a redox couple. The biosensor of the invention includes an internal reference or a reduced form of the mediator in the reagent layer on the working electrode. The internal reference is defined as an oxidizable species which in one embodiment can be further defined as a reduced form of a reversible redox couple that has an equal or higher redox potential than that of the mediator. A fixed quantitative amount of the internal reference is provided in the reagent layer. The biosensors of the invention including the internal

reference or added amount of the reduced form of mediator provide for improvements in that the internal reference acts to anchor the calibration intercept by nature of thermodynamics while maintaining the calibration slope.

Many compounds are useful as mediators due to their ability to accept electrons from the reduced enzyme and transfer them to the electrode. A necessary attribute of a mediator is the ability to remain in the oxidized state under the conditions present on the electrode surface prior to the use of the sensor. Among the more venerable mediators are the oxidized form of organometallic compounds, organic molecules, transition metal coordination complexes. A specific example of mediator is the potassium hexacyanoferrate (III), also known as ferricyanide.

As used in the following specification and claims, the term biosensor means an electrochemical sensor strip or sensor element of an analytical device or an instrument that responds selectively to analytes in an appropriate sample and converts their concentration into an electrical signal. The biosensor generates an electrical signal directly, facilitating a simple instrument design. Also, a biosensor offers the advantage of low material cost since a thin layer of chemicals is deposited on the electrodes and little material is wasted.

The term "sample" is defined as a composition containing an unknown amount of the analyte of interest. Typically, a sample for electrochemical analysis is in liquid form, and preferably the sample is an aqueous mixture. A sample may be a biological sample, such as blood, urine or saliva. A sample may be a derivative of a biological sample, such as an extract, a dilution, a filtrate, or a reconstituted precipitate.

The term "analyte" is defined as a substance in a sample, the presence or amount of which is to be determined. An analyte interacts with the oxidoreductase enzyme present during the analysis, and can be a substrate for the oxidoreductase, a coenzyme, or another substance that affects the interaction between the oxidoreductase and its substrate.

The term "oxidoreductase" is defined as any enzyme that facilitates the oxidation or reduction of a substrate. The term oxidoreductase includes "oxidases," which facilitate oxidation reactions in which molecular oxygen is the electron acceptor; "reductases," which facilitate reduction reactions in which the analyte is reduced and molecular oxygen is not the analyte; and "dehydrogenases," which facilitate oxidation reactions in which molecular oxygen is not the electron acceptor. See, for example, *Oxford Dictionary of Biochemistry and Molecular Biology, Revised Edition*, A. D. Smith, Ed., New York: Oxford University Press (1997) pp. 161, 476, 477, and 560.

The term "oxidation-reduction" reaction is defined as a chemical reaction between two species involving the transfer of at least one electron from one species to the other species. This type of reaction is also referred to as a "redox reaction." The oxidation portion of the reaction involves the loss of at least one electron by one of the species, and the reduction portion involves the addition of at least one electron to the other species. The ionic charge of a species that is oxidized is made more positive by an amount equal to the number of electrons transferred. Likewise, the ionic charge of a species that is reduced is made less positive by an amount equal to the number of electrons transferred.

The term "oxidation number" is defined as the formal ionic charge of a chemical species, such as an atom. A higher oxidation number, such as (III), is more positive, and a lower oxidation number, such as (II), is less positive. A neutral species has an ionic charge of zero. Oxidation of a species

5

results in an increase in the oxidation number of that species, and reduction of a species results in a decrease in the oxidation number of that species.

The term "redox pair" is defined as two species of a chemical substance having different oxidation numbers. Reduction of the species having the higher oxidation number produces the species having the lower oxidation number. Alternatively, oxidation of the species having the lower oxidation number produces the species having the higher oxidation number.

The term "oxidizable species" is defined as the species of a redox pair having the lower oxidation number, and which is thus capable of being oxidized into the species having the higher oxidation number. Likewise, the term "reducible species" is defined as the species of a redox pair having the higher oxidation number, and which is thus capable of being reduced into the species having the lower oxidation number.

The term "organotransition metal complex," also referred to as "OTM complex," is defined as a complex where a transition metal is bonded to at least one carbon atom through a sigma bond (formal charge of -1 on the carbon atom sigma bonded to the transition metal) or a pi bond (formal charge of 0 on the carbon atoms pi bonded to the transition metal). For example, ferrocene is an OTM complex with two cyclopentadienyl (Cp) rings, each bonded through its five carbon atoms to an iron center by two pi bonds and one sigma bond. Another example of an OTM complex is ferricyanide (III) and its reduced ferrocyanide (II) counterpart, where six cyano ligands (formal charge of -1 on each of the 6 ligands) are sigma bonded to an iron center through the carbon atoms of the cyano groups.

The term "coordination complex" is defined as a complex having well-defined coordination geometry, such as octahedral or square planar geometry. Unlike OTM complexes, which are defined by their bonding, coordination complexes are defined by their geometry. Thus, coordination complexes may be OTM complexes (such as the previously mentioned ferricyanide), or complexes where non-metal atoms other than carbon, such as heteroatoms including nitrogen, sulfur, oxygen, and phosphorous, are datively bonded to the transition metal center. For example, ruthenium hexamine, or hexaaminoruthenate (II)/(III), is a coordination complex having a well-defined octahedral geometry where six NH₃ ligands (formal charge of 0 on each of the 6 ligands) are datively bonded to the ruthenium center. Ferricyanide is also an example of the coordination complex that has the octahedral geometry. A more complete discussion of organotransition metal complexes, coordination complexes, and transition metal bonding may be found in Collman et al., *Principles and Applications of Organotransition Metal Chemistry* (1987) and Miessler & Tarr, *Inorganic Chemistry* (1991).

The term "mediator" is defined as a substance that can be oxidized or reduced and that can transfer one or more electrons between a first substance and a second substance. A mediator is a reagent in an electrochemical analysis and is not the analyte of interest. In a simplistic system, the mediator undergoes a redox reaction with the oxidoreductase after the oxidoreductase has been reduced or oxidized through its contact with an appropriate substrate. This oxidized or reduced mediator then undergoes the opposite reaction at the electrode and is regenerated to its original oxidation number.

The term "electroactive organic molecule" is defined as an organic molecule that does not contain a metal and that is capable of undergoing an oxidation or reduction reaction. Electroactive organic molecules can behave as redox species and as mediators. Examples of electroactive organic molecules include coenzyme pyrroloquinoline quinone (PQQ), benzoquinones and naphthoquinones, N-oxides, nitroso

6

compounds, hydroxylamines, oxines, flavins, phenazines, phenothiazines, indophenols, and indamines.

The term "electrode" is defined as an electrically conductive substance that remains stationary during an electrochemical analysis. Examples of electrode materials include solid metals, metal pastes, conductive carbon, conductive carbon pastes, and conductive polymers.

Having reference now to the drawings, in FIG. 1 there is illustrated a biosensor meter designated as a whole by the reference character 100 of the preferred embodiment and arranged in accordance with principles of the present invention. Biosensor meter 100 includes a biosensor 102 arranged in accordance with principles of the present invention. Biosensor meter 100 includes microprocessor 104 together with an associated memory 106 for storing program and user data. Digital data from the microprocessor 104 is applied to a digital-to-analog (D/A) converter 108. D/A converter 108 converts the digital data to an analog signal. An amplifier 110 coupled to the D/A converter 108 amplifies the analog signal. The amplified analog signal output of amplifier 110 is applied to the biosensor 102 of the invention. Biosensor 102 is coupled to an amplifier 112. The amplified sensed signal is applied to an analog-to-digital (A/D) converter 114 that converts the amplified, analog sensor signal to a digital signal. The digital signal is applied to the microprocessor 104.

Most of the commercially available disposable biosensors used for monitoring blood glucose require the deposition/printing of a mixture of an enzyme and a mediator with some binding agent. For the application of glucose measurement, the mediator is in the oxidized form of a redox couple. Depending on the redox couple, the mediator can be a very strong oxidant, such as ferricyanide, thereby chemically oxidizing the functional groups after mixing with the enzyme and the binding agent. Subsequently, a small amount of the reduced mediator is formed as impurity in the reagent in the processes of ink mixing, storage and printing. Thus, the end result of mixing and printing the reagent ink is the generation of the reduced form of the redox couple, giving rise to the background current. The formation of this reduced form of the mediator and thus the background current may vary from batch to batch. This process-generated reduced form of the mediator, such as ferrocyanide from ferricyanide, can be oxidized in general to minimize the background signal using the algorithm outlined in the U.S. Pat. Nos. 5,620,579 and 5,653,863, to Genshaw et al., and assigned to the present assignee. However, the process-dependent background signal, which is translated into the calibration intercept, can be spread out in a range of values. At the extremes of these diverged values of intercept, analytical accuracy will be suffered because no reasonable calibration intercept can be assigned to accommodate the diverged intercept.

In accordance with features of the invention, a grade of mediator that contains a certain level of the reduced form of the mediator in the reagent is used for decreasing the effect of the strong oxidant. Thermodynamically, the presence of a small amount of the reduced form of the mediator in the ink mixture of enzyme and mediator decreases the driving force for the conversion from the oxidized to the reduced form. This is advantageously accomplished by adding a small fixed amount of the reduced form of the mediator to the oxidized mediator.

Even though background signal will be generated, the algorithm in the U.S. Pat. Nos. 5,620,579 and 5,653,863 will minimize the effect of background to increase the accuracy of the glucose sensor. The above-identified patents disclose a method that reduces the background bias due to oxidizable impurities in an amperometric sensor used for measuring a

specific analyte, such as glucose, in blood. The background current of such a sensor will increase if it is stored over a long period of time or under stress (heat, moisture, etc.) due to the increased presence of reduced mediator or other reduced impurity present in the sensor such as enzyme stabilizers, e.g. glutamate, and surfactants having reducing equivalents. For example, in a ferricyanide based amperometric sensor, the background bias is related to the presence of ferrocyanide (from the reduction of ferricyanide) near the electrode surface. This accumulated ferrocyanide, as opposed to the ferrocyanide produced during use of the sensor (fresh ferrocyanide), is oxidized back to ferricyanide to reduce the background bias it causes and thereby extend the sensor shelf life. To achieve this objective, the method uses an electrochemical approach. The background bias is further reduced when the electrochemical approach is augmented with an algorithmic correction.

The disclosed method involves first applying a positive potential pulse (called the "burn-off" pulse) which precedes the normal potential profile during use of the biosensor. This is typically accomplished by applying a positive potential of from 0.1 to 0.9 volt (preferably 0.3 to 0.7 volt) between the working and reference electrodes of the sensor for a period of from 1 to 15 seconds (preferably 5 to 10 seconds). The burn-off pulse oxidizes the initial ferrocyanide (or other oxidizable impurity), so that the sensor can begin the assay with a clean background. Typically, the background is not perfectly clean since only a portion of the oxidizable impurity is oxidized by the burn-off pulse. This is the case because the chemical layer covers both the working and the counter electrodes. The initial ferrocyanide exists in the chemical layer since it comes from ferricyanide. When sample fluid is applied and the chemical layer re-hydrates, the ferrocyanide near the working electrode is re-oxidized. The rest of the ferrocyanide diffuses into the sample fluid and is mixed with the glucose. That portion of the initial ferrocyanide cannot be re-oxidized without affecting the glucose. The initial ferrocyanide is near the electrode for a very short time (a few seconds) after the fluid test sample is applied. The reason for this is that the chemicals (enzyme and ferricyanide, etc.) are deposited as a thin layer on the working and counter electrodes. The burn-off technique takes advantage of this since a significant amount of the initial ferrocyanide can be burned off without noticeable reduction of the analyte concentration in the fluid test sample most of which does not come into direct contact with the electrode. Experiments have demonstrated that the background bias of a stressed sensor can be reduced by 40% with proper application of the burn-off pulse.

The disclosed method of the U.S. Pat. Nos. 5,620,579 and 5,653,863 advantageously is applied to minimize the effect of background signal to increase the accuracy of the glucose biosensor meter **100** of the preferred embodiment. The subject matter of the above-identified patents is incorporated herein by reference.

In accordance with features of the invention, the added amount of the reduced form of mediator acts to anchor the calibration intercept by nature of thermodynamics while maintaining the calibration slope. In light of the function the reduced form of mediator, for example, ferrocyanide, plays in the glucose sensor, it is referred to as the internal reference.

Examples of electroactive organic molecule mediators are described in U.S. Pat. No. 5,520,786, issued to Bloczynski et al. on May 28, 1996, and assigned to the present assignee. In particular, a disclosed mediator (compound 18 in TABLE 1) comprising 3-phenylimino-3H-phenothiazine referred to herein as MLB-92, has been used to make a glucose biosensor **102** in accordance with features of the invention. The subject matter of the above-identified patent is incorporated herein by reference.

A commercially available biosensor meter and biosensor is manufactured and sold by Bayer Corporation under the trademark Ascensia DEX. The Ascensia DEX biosensor includes generally as pure a form of ferricyanide as possible for the reagent. The Ascensia DEX biosensor has been used to make a glucose biosensor **102** in accordance with features of the invention by adding an adequate amount of ferrocyanide to the pure ferricyanide. Benefits of adding ferrocyanide defining the internal reference of biosensor **102** to the Ascensia DEX reagent ink include an immediate benefit of increasing the intercept without changing slope, anchoring the intercept range, and increasing long-term stability of biosensor during storage.

In accordance with features of the invention, the MLB-92 mediator having a lower redox potential was used to make a glucose biosensor **102** with special properties. With the addition of adequate amounts of the internal reference, ferrocyanide, the new biosensor system can be made to work with two operation potentials: (1) at 400 mV where both the new mediator and the internal reference are oxidized, and (2) at 100 mV where only the new mediator can be oxidized. The significance of this approach is two-fold. First, the glucose biosensor **102** such formulated (new mediator and internal reference) can be operated at a high potential (+400 mV) to produce currents in a range that fits the calibration characteristics of the hardware requirements of the existing instrument. Secondly, since the lower redox potential and thus a lower oxidation power of the mediator will likely have virtually no conversion of the oxidized form to the reduced form of the mediator, a lower operation potential (0-100 mV) can be applied to the sensor so as to avoid the oxidation of the internal reference. Thus, a new set of calibration characteristics based on the new mediator, most likely with near zero intercept due to the lower oxidation power, will lead to a better analytical precision for glucose measurements. It will also reduce the matrix interference in the whole blood by avoiding the oxidation of some of the known oxidizable species such as uric acid and acetaminophen.

In accordance with features of the invention, another application of the internal reference to glucose sensors **102** is to add adequately large amount of internal reference to the biosensor system to produce a high current response. Using the double steps algorithm with open circuit between them (Bayer U.S. Pat. Nos. 5,620,579 and 5,653,863), the first potential step is set at 400 mV to produce a current that is mostly due to the internal reference signal while the second step is set at a low potential (0-100 mV) to produce a current signal related to the glucose concentration only. The ratio of the first signal, which should be virtually independent of the whole blood hematocrit, to the second signal at low potential can be used to correct for the analytical bias due to hematocrit effect.

In accordance with features of the invention, the internal reference is defined as the oxidizable species which in one embodiment is further defined as the reduced form of a reversible redox couple that has an equal or higher redox potential than that of the mediator. The concept and use of an internal reference are very common in the field of analytical chemistry. However, no example of using an internal reference for biosensors has been suggested in existing patents or literature. In all three scenarios described above, the internal reference acts to increase the response current additively for operation potentials that oxidize both species and with glucose as the analyte; a total response current is represented by:

$$I_{total} = I_{int-ref} + I_{glucose}$$

$$I_{int-ref} \propto (\text{internal reference}) \text{ and } I_{glucose} \propto (\text{glucose});$$

Where $I_{int-ref}$ is the portion of the total response current due to the internal reference, while $I_{glucose}$ is due to the oxidation of mediator proportional to the glucose concentration.

In accordance with features of the invention, the internal reference can be either the same mediator species or an oxidizable species with a higher redox potential than the mediator. Thus for biosensors with a low operation potential oxidizing only the mediator, the current $I_{int-ref}$ will be zero. However, for biosensors with a higher operation potential that oxidizes both species, the total response current will be the sum of the portion due to internal reference and that due to glucose. Since the internal reference concentration is fixed, the calibration slope of the sensor will only depend on the sensor response for glucose while the intercept will depend on the added amount of the internal reference. In other words, the internal reference will only offset the intercept and will not change the calibration slope. Thus, the concept of internal reference provides new and different ways to make glucose biosensors.

Referring now to FIGS. 1B, 1C, and 1D, there are at least three modes of operation based on the use of internal reference for glucose biosensors **102** of the invention. Potentially, the three modes of operation are represented in FIGS. 1B, 1C, and 1D. Each of the illustrated modes of operation include a first burnoff pulse, followed by a second wait period or open circuit, and a final third read pulse, each pulse or period having a selected duration, for example, 10 seconds. In the basic and most immediate operation, ferrocyanide is retained in ferricyanide at the concentration of 0.1 to 1% of the total ferricyanide providing the internal reference for glucose biosensors **102** of the invention. This is depicted in FIG. 1B where both potentials in the first and the third periods are at the same voltage, for example 400 mV. Retaining of a small percentage of ferrocyanide defining the internal reference can be accomplished either by an appropriate purification process of ferricyanide or by adding an adequate amount of ferrocyanide to the pure ferricyanide. The outcome of these retaining processes is to keep deliberately a desirable amount of ferrocyanide in ferricyanide as a special grade of ferricyanide. This is in contrast to the conventional wisdom of having as pure a form of ferricyanide as possible, such as for the DEX reagent, usually ferrocyanide in the order of 0.05% of ferricyanide or less as impurity. The most desirable amount is 0.1% ferrocyanide in the final formulation for DEX sensor, which will lead to the anchoring of the calibration intercept at a narrower range while maintaining the calibration slope for the DEX sensor.

In FIG. 1C the second mode of operation is shown, where a desirable amount of ferrocyanide (the internal reference) is added to the reagent of enzyme and a mediator with a redox potential lower than that of the internal reference. The biosensor **102** is expected to work under high and low potentials (for example at 400 mV and 100 mV vs. Ag/AgCl) for existing instruments and instruments with a new hardware requirement. This biosensor can be operated in potential programs depicted in FIG. 1B for existing instruments **100** and FIG. 1C for new instruments **100**. Examples of the mediator and internal reference combination include the system of MLB-92 and ferrocyanide as well as ruthenium hexamine and ferrocyanide. The separation of the two redox potentials is large enough so that there will be generally no oxidation of the internal reference species when operated at the low voltage.

In FIG. 1D the third mode of operation is shown, where a higher but desirable concentration of ferrocyanide is added to the reagent mixture of enzyme and a mediator with a redox potential lower than that of the internal reference. The amount of the internal reference would produce a current equivalent

to about 50% to 75% of the full scale in the calibration range preferably. In the operation algorithm, the first potential step is set to oxidize both the mediator and the internal reference (400 mV) while the second potential step for the read pulse is to oxidize the mediator only (0-100 mV). The current in the first potential step of FIG. 1D will be most pertinent to the internal reference that is immediately next to the electrode and should have virtually no hematocrit effect. The ratio of the current from the second step to that from the first step will provide a correction for the analytical bias due to hematocrit effect.

Experiments have been carried out to show the feasibility of the method of adding internal reference to a mediator system to overcome existing problems or to enhance sensor performance in accordance with the biosensor **102** of the invention.

Referring now to FIGS. 2A, 2B, and 2C, there are shown three cyclic voltammograms illustrating operation of the biosensor **102** of the invention. The illustrated three cyclic voltammograms are for MLB based glucose biosensors **102** with ferrocyanide as the internal reference in whole blood samples of 0 mg/dL glucose.

FIG. 2A illustrates working electrode vs. ferricyanide counter electrode, FIG. 2B illustrates working electrode vs. silver (Ag) and silver chloride (AgCl) or Ag/AgCl counter electrode and FIG. 2C illustrates working electrode vs. MLB-92 counter electrode. Respective peaks labeled 1 and 2 represent the oxidation of the mediator MLB_{red} (reduced form of MLB) and the internal reference ferrocyanide respectively for all three voltammogram plots. The oxidation peak for MLB_{red} shifts along the potential scale as the redox couple on the counter electrode changes from ferricyanide to Ag/AgCl to MLB-92. However, it can be seen that the relative position of the mediator MLB-92 to the internal reference ferrocyanide is the same in all three voltammogram plots of FIGS. 2A, 2B, and 2C.

Referring to FIG. 3, there shown in FIG. 3 is a chart illustrating a linear response of the biosensor **102** of the invention at different voltage operating potentials. The biosensor **102** is operated at (1) 400 mV potential and (2) 150 mV potential. FIG. 3 illustrates the linear dose response of MLB-92 mediator based biosensor **102** with 20 mM ferrocyanide as the internal reference. Respective lines labeled EXAMPLE 1 and EXAMPLE 2 are from 400 mV and 150 mV operation potentials against Ag/AgCl counter electrode. As shown in FIG. 3, the biosensor **102** gives virtually the same slope but with different intercepts for operations at 400 mV and 150 mV potentials. This result demonstrates that the internal reference can be selectively oxidized or avoided by the operation potential. Thus, one biosensor **102** can serve for two different meters.

Examples of the biosensor **102** have been prepared systematically showing the increase of intercept with increasing ferrocyanide as the internal reference while the slopes were kept virtually unchanged. Three working electrode reagents were prepared in the following formulations. These three reagents were pin-deposited on to two sensor formats: (1) Ag/AgCl as the counter electrode, (2) 10% printed ferricyanide as the counter electrode.

Formulations	Enzyme, PQQ- GDH	Mediator MLB-92	Internal Reference Ferricyanide	Buffer and binding agent,
1	20 unit/ μ L	24 mM	0 mM	0.1M NaCl + phosphate, 1% CMC

11

-continued

Formulations	Enzyme, PQQ- GDH	Mediator MLB-92	Internal Reference Ferriocyanide	Buffer and binding agent,
2	20 unit/ μ L	24 mM	4 mM	0.1M NaCl + phosphate, 1% CMC
3	20 unit/ μ L	24 mM	8 mM	0.1M NaCl + phosphate, 1% CMC

FIG. 4 illustrates effect of the added internal reference to the overall voltammetric current using biosensors 102 of the invention with 10% printed ferricyanide as the counter electrode. FIG. 4 provides cyclic voltammograms of sensors with ferrocyanide as the internal reference in whole blood samples of 0 mg/L glucose. Voltammograms labeled A, B and C are with formulations 1, 2 and 3 respectively all with a counter electrode of 10% printed ferricyanide.

The effect of the added internal reference to the overall voltammetric current is shown in FIG. 4 using sensors with 10% printed ferricyanide as the counter electrode. The main oxidation/reduction peaks here are centered around -0.38 Volt vs. 10% ferricyanide, which is due to the mediator MLB. The oxidation peak at about 0-50 mV is due to the internal reference of ferrocyanide. While the oxidation peak for the internal reference ferrocyanide increases with the increases of the internal reference concentration from 0 to 4 to 8 mM, the oxidation peak for the mediator is virtually unchanged. Here the concept of internal reference is explained further by the fact that the main oxidation peak of MLB_{red} is unaffected by the presence of the internal reference.

Referring to FIGS. 5A and 5B, charts illustrating linear response and increased intercept with increasing internal reference of MLB based biosensors 102 of the invention with Ag/AgCl as the counter electrode are shown. FIG. 5A illustrates the linear dose response of MLB based biosensors 102 with 0, 4, and 8 mM ferrocyanide, respectively labeled EXAMPLE 1, EXAMPLE 2, and EXAMPLE 3. FIG. 5B illustrates intercept and slope as a function of added ferrocyanide in the working electrode reagent of the biosensor 102 of the invention. All three sensors used Ag/AgCl as the counter electrode.

Referring also to FIGS. 6A and 6B, charts illustrating linear response and increased intercept with increasing internal reference of MLB based biosensors 102 of the invention with 10% ferricyanide as the counter electrode are shown. FIG. 6A illustrates the linear dose response of MLB based biosensors 102 with 0, 4, and 8 mM ferrocyanide, respectively labeled EXAMPLE 1, EXAMPLE 2, and EXAMPLE 3. FIG. 6B illustrates intercept and slope as a function of added ferrocyanide in the working electrode reagent of the biosensor 102 of the invention. All three sensors used 10% printed ferricyanide as the counter electrode.

In the dose response experiments, both sensor series with Ag/AgCl counter electrode of FIGS. 5A and 5B, and 10% ferricyanide counter electrode of FIGS. 6A and 6B show linear response and increased intercept with increasing internal reference. For practical purpose, the slope of the three sensors in FIGS. 5A and 5B is unchanged while the intercept increases linearly with the added ferrocyanide. The same linear relationship of intercept with added ferrocyanide and the flat slope trend are repeated in sensor series with the % printed ferricyanide as the counter electrode, as shown in FIGS. 6A and 6B.

12

Experiments have been carried out to show the addition of ferrocyanide to DEX reagent ink, modification of calibration intercept without changing slope in accordance with the biosensor 102 of the invention.

FIG. 7 illustrates linear relationship of the calibration intercept with increasing internal reference of DEX type biosensors 102 of the invention. Five different formulations in a set format labeled BC7 in FIG. 7 were made with 0, 0.02, 0.04, 0.06 and 0.08% ferrocyanide mixed in the standard DEX reagent for the DEX sensor. The regression slope and intercepts for these five sensors of the BC7 format are shown in FIG. 7. Except for sensor with 0.06% ferrocyanide due to the experimental problems, the intercepts of the other four sensors give a nice linear function with respect to the added amount of ferrocyanide as the internal reference. On the other hand, the slopes of all five sensors fall in a flat line indicating that the addition of the internal reference does not change the slope of the DEX type biosensors 102 of the invention.

FIGS. 8A and 8B illustrate the ratio of signal to reference results from flow-injection-analysis (FIA) of the residual ferrocyanide from a control reagent ink and the reagent ink with 0.1% ferrocyanide added to the reagent mixture of 20% ferricyanide of a biosensor 102 of the invention. One of the subtle effects of adding the internal reference ferrocyanide to the DEX reagent ink is to decrease the driving force for the conversion of the mediator ferricyanide to ferrocyanide. Thus, ferricyanide becomes the source of the residual current in the DEX sensor. One way of showing this subtle effect is to monitor the increase of the residual current (background current) of the reagent ink with internal reference along with the control reagent ink over a long period of time. Both reagent inks were stored in refrigeration ($2-8^{\circ}\text{C}.$) over several weeks. FIG. 8 shows the results of FIA of the residual ferrocyanide from both reagent inks. From FIG. 8, the ratio of signal-to-reference (S/R) represents the relative amount of ferrocyanide from the reagent ink compared to the added ferrocyanide as the reference in FIA. Thus, the higher the value of S/R from the FIA analysis, the higher the ferrocyanide in the reagent inks. It can be seen from FIG. 8A that the S/R value increase over the period of six weeks for both the control inks and the reagent ink with added ferrocyanide. However, the reagent ink curve with added ferrocyanide has a slower increase of residual current over the period of six weeks compared to control curves. In FIG. 8B, the S/R response curves from the control inks and the reagent ink with added ferrocyanide are merged together for comparison. To the first order approximation (since the coefficients for the second order terms of both second order polynomials are very small), the rate of residual current increase over six weeks during refrigeration is about 30% ($[0.0918-0.0638]/0.0918=30\%$) smaller for the reagent ink curve with added ferrocyanide than for the control curves. Thus, it may be understood from FIGS. 8A and 8B that the rate of the ferricyanide-to-ferrocyanide conversion in reagent ink is decreased substantially by the addition of the internal reference ferrocyanide to the DEX reagent ink in accordance with biosensor 102 of the invention.

While the present invention has been described with reference to the details of the embodiments of the invention shown in the drawings, these details are not intended to limit the scope of the invention as claimed in the appended claims.

What is claimed is:

1. A method of using a biosensor including a mixture of an only one enzyme, a mediator, and an oxidizable species as an internal reference, said oxidizable species being different than the mediator species and having different redox poten-

13

tials, wherein said mixture is located directly on a surface of at least a portion of a working electrode, said method comprising the steps of:

applying a first voltage potential in a first voltage period; providing a set delay period; applying a second voltage potential in a second voltage period following said delay period; and wherein said first voltage potential and said second voltage potential are selectively provided for oxidizing only said mediator or both said mediator and said internal reference.

2. The method of claim 1 wherein the step of applying said first voltage potential in said first voltage period includes the step of applying a selected first voltage potential in said first voltage period for oxidizing said mediator and said internal reference.

3. The method of claim 1 wherein the step of applying said first voltage potential in said first voltage period includes the step of applying a selected first voltage potential in said first voltage period for oxidizing only said mediator.

4. The method of claim 1 wherein the step of applying said second voltage potential in said second voltage period following said delay period includes the step of applying a selected second voltage potential for oxidizing said mediator and said internal reference.

5. The method of claim 1 wherein the step of applying said second voltage potential in said second voltage period following said delay period includes the step of applying a selected second voltage potential for oxidizing only said mediator.

6. The method of claim 1 wherein the steps of applying said first voltage potential and applying said second voltage potential includes the steps of applying a selected voltage potential in a range between 100 mV and 400 mV.

7. The method of claim 1 wherein the steps of applying said first voltage potential and applying said second voltage potential includes the steps of applying a selected first voltage potential in said first voltage period for oxidizing both said mediator and said internal reference; and applying a selected second voltage potential for oxidizing only said mediator.

8. The method of claim 1 wherein the biosensor includes a mediator comprising 3-phenylimino-3H-phenothiazine; and wherein said internal reference comprises ferrocyanide.

9. The method of claim 1 wherein the steps of applying said first voltage potential and applying said second voltage potential includes the steps of applying a selected first and second voltage potential for oxidizing both said mediator and said internal reference; wherein said internal reference effectively anchoring a calibration intercept within a narrow range and said internal reference effectively maintaining a calibration slope for the biosensor.

10. The method of claim 1 wherein said mediator comprises ruthenium hexamine, and wherein said internal reference comprises ferrocyanide.

11. The method of claim 1 wherein said internal reference comprises ferrocyanide.

12. The method of claim 1 wherein said mediator comprises 3-phenylimino-3H-phenothiazine.

13. The method of claim 1 wherein said mediator comprises ruthenium hexamine.

14. The method of claim 1 wherein the steps of applying said first voltage potential and applying said second voltage

14

potential includes the steps of applying a selected voltage potential in a range between 0 mV and 400 mV.

15. A method of using a biosensor to assist in determining glucose concentration, the method comprising:

providing a biosensor including a reagent, located directly on a surface of at least a portion of a working electrode, the reagent including an only one enzyme, mediator and an oxidizable species as an internal reference, said oxidizable species being different than the mediator species and having different redox potentials;

applying a first voltage potential in a first voltage period; providing a set delay period; and

applying a second voltage potential in a second voltage period following said delay period,

wherein said first voltage potential is selectively provided for oxidizing only said mediator or both said mediator and said internal reference, and wherein said second voltage potential is selectively provided for oxidizing only said mediator or both said mediator and said internal reference.

16. The method of claim 15 wherein the enzyme includes glucose oxidase.

17. The method of claim 15 wherein enzyme includes glucose dehydrogenase.

18. The method of claim 15 wherein said mediator reference comprises 3-phenylimino-3H-phenothiazine.

19. The method of claim 18 wherein said internal reference is ferrocyanide.

20. The method of claim 15 wherein the steps of applying said first voltage potential and applying said second voltage potential includes the steps of applying a selected voltage potential in a range between 0 mV and 400 mV.

21. A method of using a biosensor to assist in determining an analyte concentration, the method comprising:

providing a biosensor including a reagent, the reagent, located directly on a surface of at least a portion of the working electrode, including only one enzyme, mediator and an oxidizable species as an internal reference;

applying a first voltage potential in a first voltage period; providing a set delay period; and applying a second voltage potential in a second voltage period following said delay period;

wherein one of said first voltage potential and said second voltage potential oxidizes only said mediator and the other one of said first voltage potential and said second voltage potential oxidizes both said mediator and said internal reference.

22. The method of claim 21 wherein the analyte is glucose.

23. The method of claim 22 wherein the enzyme includes glucose oxidase or glucose dehydrogenase.

24. The method of claim 21 wherein said mediator reference comprises 3-phenylimino-3H-phenothiazine.

25. The method of claim 21 wherein the steps of applying said first voltage potential and applying said second voltage potential includes the steps of applying a selected voltage potential in a range between 100 mV and 400 mV.

26. The method of claim 21 wherein said first voltage potential oxidizes both said mediator and said internal reference and said second voltage potential oxidizes only said internal reference.

* * * * *